|
Company:
|
SESEN BIO, INC. (SESN)
|
|
Form Type:
|
8-K
|
|
Filing Date:
|
6/23/2022
|
|
CIK:
|
0001485003
|
|
Address:
|
245 FIRST STREET
SUITE 1800
|
|
City, State, Zip:
|
CAMBRIDGE, Massachusetts 02142
|
|
Telephone:
|
617-444-8550
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$0.81
|
Change:
-0.004 (-0.44%)
|
Trade Time:
Jun 27
|
Market Cap:
$162.36M
|
|
|
|
|
|
|
Description of Business
|
|
We are a late-stage clinical company advancing targeted fusion protein
therapeutics ("TFPTs") for the treatment of patients with cancer. We genetically
fuse the targeting antibody fragment and the cytotoxic protein payload into a
single molecule which is produced through our proprietary one-step, microbial
manufacturing process. We target tumor cell surface antigens with limited
expression on normal cells. Binding of the target antigen by the TFPT allows for
rapid internalization into the targeted cancer cell. We have designed our
targeted proteins to overcome the fundamental efficacy and safety challenges
inherent in existing antibody-drug conjugates ("ADCs") where a payload is
chemically attached to a targeting antibody.
|
|
|
|